Kornimate/medical-research-clean huggingface dataset:
oxygen supplementation and ventilator hyperinflation in the endotracheal suction (osvhes)

Conditions: Hypoventilation; Hypoxemia

Summary: this is a double crossover study where all patients are randomly allocated to one of two treatment sequences associated with endotracheal aspiration.the first treatment (a) uses two suctioning methods for each patient: one involving hyperoxygenation with administration of 100% oxygen 1 minute before and after suction (intervention i), and the other hyperoxygenation with oxygen supply to 20% above basal offer (intervention ii) in the same way.the second treatment (b) uses a technique of hyperinflation with the mechanical ventilator (peep-zeep) associated with hyperoxygenation. the intervention i, uses peep-zeep offering 20% above basal oxygenation and intervention ii uses the peep-zeep with basal oxygen supply in the same way. all subjects were randomly allocated using sealed envelopes to a treatment sequence a or b on day 1. patients received two treatments, at least four hours apart. the first treatment is in the morning and the alternate treatment is performed in the afternoon. on day 2 the order of the treatments was reversed using the same patient position sequence.the interventions i and ii are performed at least 4 hours apart to minimize any carryover effect.

endotracheal suction must be carried out only through precise indication, because it is associated with undesirable effects on the hemodynamic parameters, ventilation, oxygenation and respiratory mechanics. the hyperoxygenation is one of the methods of prevention of hypoxemia induced by tracheal suction procedure and have been proposed for its efficiency. another method is the hyperinflation with the mechanical ventilator. ventilator hyperinflation improves oxygenation, mobilizes the bronchial secretion excess and re-expand the lung collapsed areas. the peep-zeep is a ventilator hyperinflation technique, described as a lung inflation through a positive pressure enhancement at the end of expiration (peep), followed by rapid lung deflation with an abrupt reduction in the peep to zeep (0 centimeters of water (cmh2o)).

Eligibility criteria:
inclusion criteria: * mechanical ventilation for more than 12h * hemodynamic stability * presence of indication criteria of endotracheal aspiration procedure exclusion criteria: * high doses of vasopressor amines amines and/or severe arrhythmias * hemoglobin \< 7 g/dl * fio2 ≥ 0.6 * peep ≥ 10 cmh2o * conditions: rib fractures, chest drain, severe bronchospasm, pneumothorax not drained and tracheostomy * contraindications of ventilator hyperinflation(peep-zeep): intracranial pressure \> 10 mmhg, bleeding disorders, accented degrees of gastroesophageal reflux and bullous lung disease.

Keywords: respiratory mechanics oxygenation suction mechanical ventilation respiratory therapy capnography pulmonary ventilation
effect of quercetin supplements on healthy males: a four-week randomized cross-over trial

Conditions: Hyperuricemia; Gout; Kidney Calculi; Diabetes; Cardiovascular Disease

Summary: the purpose of this study was to test the effect of chronic consumption of quercetin 500 mg tablets on blood uric acid and other biomarkers in adult males.

the main goal of the research is to determine the long term effects of daily supplementation of quercetin, a compound naturally and normally present in food, on the chemical composition (uric acid ii and glucose) of blood and urine and on blood pressure, of healthy males. six of the volunteers will collect urine after consuming a standard meal made from fresh onion and after quercetin supplement intake, in the same way, with 3 days washout before each. the urine collected here will be analysed to check that the supplement is equivalent to the food. stage 2 will only be conducted with supplement and placebo. healthy male volunteers with higher (than average) blood uric acid will be selected and will be asked to consume a standard supplement/placebo added to their own diet for 4 weeks per phase. two arms are separated by 4 weeks resting period: quercetin supplement and placebo. blood and urine samples will be taken every other week to detect any changes of uric acid and other biomarkers. ----- i) quercetin is found in a variety of foods including apples, berries, brassica vegetables, capers, grapes, onions, shallots, tea, and tomatoes, as well as many seeds, nuts, flowers, barks, and leaves. ii) uric acid, a compound found in both in the human body and urine, is produced by the breakdown of purines, which are nitrogen-containing compounds in substances such as nucleic acids (dna). they enter the circulation from digestion of certain foods, drinks (alcoholic beverages like beer and wine) or from normal breakdown and turnover of cells in the body. most uric acid is removed by the kidneys and disposed of in the urine; the remainder is excreted in the stool.

Eligibility criteria:
inclusion criteria: * written informed consent * plasma uric acid \> 300 micro mole/l * generally healthy exclusion criteria: * body mass index (bmi) ≥ 30 kg/m² or \<18.5 kg/m² * unable or unwilling to comply with the protocol, or likely to leave the study before its completion. * who would undertake important change in physical exercise or vigorous sport competitions during the study period. * regularly drink more than 3 units of alcohol every day * smokers * have history of treated hyperuricemia, gout and/ or kidney stone * have intestinal disorders

Keywords: functional food
pilot clinical study of the lrs thermosuit™ system in post arrest patients

Conditions: Cardiac Arrest; Comatose

Summary: the purpose of this study is to determine if the life recovery systems thermosuit(r) system is able to quickly and conveniently cool patients who are comatose after resuscitation from cardiac arrest.

the primary purpose of this study is to clinically evaluate the use of a new cooling device (the lrs thermosuit(r) system) to cool patients who are comatose following resuscitation from cardiac arrest. this device cools by circulating cold water directly against the skin of the patient. cooling to a state of mild hypothermia (32 to 34 degrees c, maintained for 12 to 24 hours) is recognized by the american heart association, european resuscitation council, and the canadian association of emergency care physicians as a promising therapy for such patients, and is likely to be most effective if administered quickly following resuscitation. it is hypothesized that this new device will cool patients much more quickly than by historical means. patients will be monitored for physiologic parameters such as body temperature during the cooling therapy, and will be tracked for neurological outcomes following treatment.

Eligibility criteria:
inclusion criteria: * cardiac arrest prior to or during hospital admission, with restoration/return of spontaneous circulation (rosc). * initial (pre-resuscitation) cardiac rhythm of ventricular fibrillation, non-perfusing ventricular tachycardia, pulseless electrical activity, or asystole. * estimated or known age \> 18 years. * intubation, ventilation and placement of esophageal probe. * persistent neurologic dysfunction i.e. comatose upon enrollment \[gcs ≤ 8\]. exclusion criteria: * height greater than 188 cm. * elbow-to-elbow width greater than 60 cm (as measured above the supine patient). * core temperature less than 35°c after rosc (as measured at the tympanic membrane, esophagus, sub-lingual space,nasopharynx, or central blood vessel). * comatose state before the cardiac arrest due to the administration of drugs that depress the central nervous system. * known pregnancy. * response to verbal commands after rosc (but before enrollment). * known terminal illness that preceded the arrest. * known enrollment in another study of a device, drug, or biologic. * major trauma or other co-morbidity requiring urgent surgery. * improving neurologic status. * \> 4 hours since return of spontaneous circulation. * unknown time of arrest. * severe or known coagulopathy (with active bleeding). * hemodynamic instability despite vasopressors (sbp \ 30 minutes after rosc and before enrollment).

Keywords: resuscitation hypothermia
autologous cartmeso/19 against pancreatic cancer

Conditions: Pancreatic Cancer

Summary: pancreatic cancer patients receive chimeric antigen receptor (car) t cells against mesothelin (cartmeso) or cd19 (cart19) cells administered at 3 days via pancreatic artery infusion or i.v. after preconditioning of cyclophosphamide. both cart cells are autologous. cartmeso cells target pancreatic cells which highly express mesothelin, while cart19 cells target tumor-associated b cells expressing cluster of differentiation antigen 19 (cd19) which are mostly immunosuppressive. the investigators hypothesize that this combination therapy may enhance the efficacy of cartmeso cells in the body. additionally, a medium dose of cyclophosphamide is used to enhance the engraftment of cart cells.

this is a single arm, open-label, pilot study to determine the safety and feasibility of combination cartmeso cells and cart19 cells in patients with pancreatic cancer following lymphodepletion with cyclophosphamide. both cells contain car proteins consisting of a murine-derived single chain antibody fragment (scfv), cluster of differentiation antigen 137 (41bb) co-stimulatory domain and cluster of differentiation antigen 3 zeta chain (cd3ζ) signaling domain transduced by lentivirus

Eligibility criteria:
inclusion criteria: * signed informed consent * serum soluble mesothelin-related protein (smrp) \> 0.4 nanomolar/l * persistent cancer after at least one prior standard of care chemotherapy for advanced stage disease * 18 years of age and ≤65 * life expectancy greater than 3 months * satisfactory organ and bone marrow function exclusion criteria: * participation in a therapeutic investigational study within 4 weeks prior to the screening visit * active invasive cancer other than pancreatic cancer * hiv, hepatitis b/c virus, or infections * active autoimmune disease requiring immunosuppressive therapy within 4 weeks * planned concurrent treatment with systemic high dose corticosteroids * patients requiring supplemental oxygen therapy * pregnant or breastfeeding women

Keywords: cart pancreatic cancer artery infusion
follow-up of patients with uveal melanoma adapted to the risk of relapse (salome)

Conditions: Uveal Melanoma

Summary: biomarkers search for early diagnosis of liver metastases in patients with uveal melanoma who benefit from a follow-up tailored to their personalized risk of relapse.

high risk patients are referred for the medical oncology consultation to organize oncological surveillance after general staging of the disease. signature of the informed consent of salome study, inclusion in the study and risk-adjusted surveillance schedule : (i) liver mri every 6 months performed at the expert center for um (according to guidelines). (ii) for enucleated patients, a blood sample (3 x 6 ml edta tubes) is taken every 6 months according to the schedule below. plasma and mononucleated cells will be isolated and preserved for bio-markers research. * m0 : during the first medical oncology visit. * at each imaging assessment, every 6 months for at least 5 years (m6 to m60) and 10 years maximum (m120). * at the diagnosis of metastasis. * at each significant event during the metastatic disease (surgery, treatment response or progression).

Eligibility criteria:
inclusion criteria: 1. patient aged of 18 years or more. 2. patient with uveal melanoma with high metastatic relapse risk defined as : * t2b/c/d ou ≥ t3, * or chromosom 3 or chromosom 8 abnormality by cgh array. 3. completion of treatment of the primary tumor ≤ 2 months. 4. patient able to comply with the schedule of visits and blood samples of the study. 5. signed informed consent form or legal representative. exclusion criteria: 1. patient without french social insurance. 2. any social, medical or psychological condition making the research process impossible.

Keywords: uveal melanoma
achieving blood pressure control together study

Conditions: Hypertension

Summary: african americans represent a particularly vulnerable subgroup of persons with hypertension, as they are more likely than whites to have hypertension, equally as likely to be aware of it and to be treated for it, but less likely to achieve blood pressure control while receiving treatment. african americans are also more likely than whites to suffer end organ damage as a result of hypertension. patients' hypertension self-management behaviors (including adherence to prescribed care, self-blood pressure monitoring, lifestyle changes, and shared medical decision-making) represent a cornerstone of hypertension therapy. evidence suggests some african americans with hypertension may experience difficulties carrying out positive self-management behaviors, in part due to cultural beliefs and practices, knowledge and perceptions regarding the nature and consequences hypertension, and lack of systems to support ongoing engagement in prescribed care within their communities. substantial evidence has demonstrated the important role of family and community support in improving patients' management of a variety of chronic illnesses. the goal of this study is to rigorously test the effectiveness of hypertension self-management interventions that engage african american patients, their families, and their community-level resources to improve african american patients' blood pressure. we hypothesize patients' hypertension control rates may be improved when combining community health worker self-management support with other types of hypertension self-management skills training.


Eligibility criteria:
inclusion criteria: * 18 years and above * african american/black * english speaking * two blood pressure values \>=140/\>=90 in 6 months prior * seen at east baltimore medical center exclusion criteria: * 18 years and less * non african american/black * not english speaking * pregnant
low frequency, ultra-low tidal volume ventilation in patients with ards and ecmo

Conditions: ARDS; Acute Lung Injury; Extracorporeal Membrane Oxygenation; Respiratory Distress Syndrome; Respiratory Tract Diseases; Lung Diseases; Lung Injury, Acute

Summary: the acute respiratory distress syndrome (ards) is the most severe form of respiratory failure, presented in 10% of all intensive care patients and carrying a high mortality rate. extracorporeal membrane oxygenation (ecmo) is a rescue treatment for patients with severe ards. mechanical ventilator settings in patients with severe ards during ecmo therapy are not clearly defined at the moment.

the aim of this study is to assess the effect of a rigorous low breathing frequency and ultra-low tidal volume ventilation strategy on clinical outcome, compared to standard ventilator settings following the recent guidelines in patients with severe ards treated with ecmo. the hypothesis is that a low breathing frequency and ultra-low tidal volume ventilation strategy is more protective for the ards challenged lung and reduces the duration of mechanical ventilation and so increases the ventilator free days in patients with severe ards treated with ecmo.

Eligibility criteria:
inclusion criteria: * moderate to severe ards - partial pressure of oxygen/fraction of inspired oxygen (pao2/fio2) \< 200 mmhg * ecmo \< 24 hours in situ * gender-matched * age-matched exclusion criteria: * bmi \> 40 * expected weaning of ecmo \< 3 days (postoperative ecmo) * combustion * restrictive chest wall impairment * pregnancy

Keywords: ards, ecmo, ventilation
evaluation of daytime corneal swelling during wear of galyfilcon a lenses

Conditions: Myopia

Summary: the purpose of this study is to evaluate corneal swelling, limbal redness, and endothelial bleb response to wearing galyfilcon a lenses in asian eyes.


Eligibility criteria:
inclusion criteria: * be of legal age (i.e. 18 years) * be of asian descent and have -asian eye‖ identifying features (see appendix a) * be mentally competent, willing and able to sign a written informed consent form. * have contact lens distance sphere requirement in the range 1.00d to 6.00d. * have spectacle astigmatism \<1.25d in each eye * currently wear soft contact lenses (for at least 3 months prior to the trial ) without experiencing difficulties or contact lens related complications * have had an oculo-visual examination within the previous 12 months. * have normal eyes with no evidence of abnormality or disease. for the purposes of this study a normal eye is defined as one having: * no evidence of lid abnormality or infection * no conjunctival abnormality or infection * no clinically significant slit lamp findings (i.e. edema, staining, scarring, vascularization, infiltrates or abnormal opacities) * no other active ocular disease exclusion criteria: * requires concurrent ocular medication. * clinically significant (grade 3 or 4) corneal staining (fda scale), corneal stromal haze, corneal vascularization, tarsal abnormalities, bulbar hyperemia, limbal hyperemia, or any other abnormality of the cornea that would contraindicate contact lens wear. * has had refractive surgery. * has had any anterior ocular surgery. has had any other ocular surgery or injury within 8 weeks immediately prior to enrolment for this study. * history of abnormal lachrymal secretions. * pre-existing ocular irritation that would preclude contact lens fitting. * keratoconus or other corneal irregularity. * extended lens wear in last 3 months. * pmma, hybrid or rgp lens wear in the previous 8 weeks * any systemic illness which would contraindicate lens wear or the medical treatment of which would affect vision or successful lens wear. * has diabetes * known/reported infectious disease (e.g., hepatitis, tuberculosis) or an immunosuppressive disease (e.g., hiv). * history of chronic eye disease (e.g. glaucoma or armd). * pregnancy, lactating, or planning a pregnancy at the time of enrolment. * participation in any concurrent clinical trial or in last 30 days. * family member or employee of the clinical site, investigator or other study staff. * currently wears habitual contact lenses on an ew basis.
comparing efficacy of prp combined with different hyaluronan for the treatment of knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: either prp or ha is each effective for treating knee oa. however, the efficacy of combined prp and ha injections remains unknown clinically.

intraarticular plasma-rich platelet (prp) or hyaluronic acid (ha) was each effective for knee osteoarthritis(oa). the efficacy of combined injections remains unknown. this study aimed to evaluate the efficacy of prp combined with different hyaluronan for treating knee oa. in a prospective, randomized-controlled trial, 95 patients with kellgren-lawrence grade 2 knee oa were randomized to receive a single intraarticular artz (10mg/ml) followed by prp (n=48) into target knee or single hyajoint plus (20mg/ml) injection followed by prp (n=47). primary outcome was the change from baseline in the visual analog scale (vas) pain at 6 months. secondary outcomes included the western ontario and mcmaster universities osteoarthritis index (womac), lequesne index, single leg stance test (sls), use of rescue analgesics and patient satisfaction.

Eligibility criteria:
inclusion criteria: * age of 20-85 years symptomatic knee osteoarthritis for more than 6 months despite analgesics, nsaids, or physical therapy kellgren-lawrence grade-2 knee osteoarthritis seen on radiographs made within previous 6 months radiological evidence of bilateral knee oa was accepted if global pain vas in the contralateral knee was less than 30 mm. exclusion criteria: * previous orthopedic surgery on spine or lower limb disabling osteoarthritis of either hip or foot knee instability, apparent joint effusion, or marked valgus/varus deformity known allergy to avian proteins or hyaluronan products confirmed or suspected pregnancy, or lactating intra-articular injections into knee in previous 6 months any specific medical conditions (rheumatoid arthritis, active infection, hemiparesis, neoplasm, hematological etc.) that would interfere with assessments

Keywords: hyaluronic acid knee osteoarthritis platelet-rich plasma
inflammation and vascular function in atherosclerosis

Conditions: Atherosclerosis

Summary: the purpose of this study is to determine whether reducing inflammation in blood vessels with an aspirin-like drug called salsalate will improve blood vessel function.

to test the hypothesis that inhibition of i \[kappa\] b kinase \[beta\] (iĸkβ), an inflammatory mediator, by high dose salsalate, will restore insulin-mediated endothelium-dependent vasodilation in subjects with atherosclerosis.

Eligibility criteria:
inclusion criteria: * non-smoking adult subjects with known atherosclerosis exclusion criteria: * uncontrolled hypertension (\> 140/90 mmhg) * untreated hypercholesterolemia (ldl \> 160 mg/dl) * diabetes mellitus * alanine aminotransferase \> 150 * creatinine \> 1.4 mg/dl * concommitant use of warfarin

Keywords: vascular inflammation endothelium-dependent flow-mediated blood vessel function
the effect of erythromycin on occurrence of leaks from cervical esophageal-gastric anastomosis after trans-hiatal esophagectomy

Conditions: Esophagectomy; Postoperative Complications

Summary: cervical anastomotic leak is one of the most common complications after trans-hiatal esophagectomy. hypothesis: an early post operative administration of a pro-kinetic dosage of erythromycin will reduce leak occurrence. design: this is a prospective, randomized, double blind, placebo controlled study. number of patients: 30. inclusion criteria: * patients after trans-hiatal esophagectomy exclusion criteria: * allergy to erythromycin * use of phenothiazine * qt prolongation * liver function test (lft) abnormalities * myasthenia gravis * cardiomyopathy


Eligibility criteria:
inclusion criteria: * patients after trans-hiatal esophagectomy exclusion criteria: * allergy to erythromycin * use of phenothiazine * qt prolongation * liver function test (lft) abnormalities * myasthenia gravis * cardiomyopathy
biomarkers of antidepressant response and suicidal events in depressed youth

Conditions: Depression; Adolescent

Summary: the aims of this study are to (1) identify inflammatory/neurotrophic and neurodevelopmental markers that predict antidepressant response and suicidal risk in depressed youth and (2) predict their treatment response and the occurrence of suicidal events at the individual level using machine learning approach.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of major depressive disorder(mdd) according to criteria of diagnostic and statistical manual of mental disorders, fifth edition (dsm-5) * current episode at least 4 weeks in duration at baseline * with a score of at least 40 on the children's depression rating scale-revised (cdrs-r), and cgi-severity ≥4 at baseline exclusion criteria: * intelligence quotient (iq) lower than 70 * psychotic features or first-degree relatives with a history of bipolar i disorder * alcohol or substance abuse within the past 6 months * history of schizophrenia, bipolar disorder, eating disorder, or autism * history of neurological diseases including convulsive disorders or brain damage * concurrent medications with psychotropic effects (other than stimulants for adhd) * chronic medical conditions (e.g., asthma, inflammatory bowel disease, diabetes) and/or chronic medication with psychotropic effects (e.g., anticonvulsants) or chronic use of nsaids or other drugs with known impact on inflammatory pathways.

Keywords: depression adolescent biomarker inflammation brain-derived neurotrophic factor (bdnf) functional mri antidepressant machine learning